A review of peritoneal mesothelioma at the Washington Cancer Institute.
This article reviews a single institution's experience with 68 patients (21 females, 47 males) prospectively treated over the last 2 decades with an aggressive local-regional approach, combining maximal cytoreductive surgery with heated intraoperative intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy. This multimodality treatment has resulted in a median survival of 67 months. Female patients had a significantly better prognosis than males. The other significant predictive factors of survival were: age, diagnosis by incidental findings, tumor extent, pathology, and completeness of cytoreduction.
Sugarbaker
Paul H
PH
Program in Peritoneal Surface Malignancy, Washington Cancer Institute, 110 Irving St., NW, Washington, DC 20010, USA. Paul.Sugarbaker@medstar.net
Welch
Laura S
LS
Mohamed
Faheez
F
Glehen
Olivier
O
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001707:Biopsy, Needle; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy / Q000379:methods; D004219:District of Columbia; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D008875:Middle Aged; D009316:National Institutes of Health (U.S.); D009367:Neoplasm Staging; D010534:Peritoneal Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D010537:Peritoneum / Q000473:pathology / Q000601:surgery*; D011379:Prognosis; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States